

# Impact of ABO Compatibility on Heart Transplantation Outcomes in a Nationwide Cohort Study Over the Last Decade

Oliver Kayden Jawitz<sup>1,3</sup>; Nicole Gong<sup>2</sup>; Lavanya Bellumkonda, MD<sup>3</sup>; Daniel Jacoby, MD<sup>3</sup>; Daniel Dries, MD<sup>3</sup>; Forrester Lee, MD<sup>3</sup>; David Yuh, MD<sup>3,4</sup>; Pramod Bonde, MD<sup>1,3,4,5</sup>

- <sup>1</sup>Heart Transplantation Laboratory, Yale School of Medicine
  - <sup>2</sup>MD/PhD Program, Penn State College of Medicine
  - <sup>3</sup>Yale School of Medicine
  - <sup>4</sup>Section of Cardiac Surgery, Yale School of Medicine
  - <sup>5</sup>Yale Center for Advanced Heart Failure, Mechanical Circulatory Support, and Heart Transplantation
- AATS Annual Meeting - May 7, 2013

# Impact of ABO Compatibility on Heart Transplantation Outcomes in a Nationwide Cohort Study Over the Last Decade

*Oliver Kayden Jawitz<sup>1,3</sup>; Nicole Gong<sup>2</sup>; Lavanya Bellumkonda, MD<sup>3</sup>; Daniel Jacoby, MD<sup>3</sup>; Daniel Dries, MD<sup>3</sup>; Forrester Lee, MD<sup>3</sup>; David Yuh, MD<sup>3,4</sup>; Pramod Bonde, MD<sup>1,3,4,5</sup>*

*<sup>1</sup>Heart Transplantation Laboratory, Yale School of Medicine*

*<sup>2</sup>MD/PhD Program, Penn State College of Medicine*

*<sup>3</sup>Yale School of Medicine*

*<sup>4</sup>Section of Cardiac Surgery, Yale School of Medicine*

*<sup>5</sup>Yale Center for Advanced Heart Failure, Mechanical Circulatory Support, and Heart Transplantation*

*AATS Annual Meeting - May 7, 2013*





Disclosures:

*None*

# Background


- Approx 2,000 heart tx annually (USA)
  - ~10% of recipients do not survive the first year
- Demand vs. supply: donor hearts
  - As of March 2013, 3,481 patients waiting for a heart transplant\*
- Optimum and efficient allocation
- Are ABO compatible donor/recipient matches associated with worse outcomes compared with ABO identical matches?
  - Previous studies have shown conflicting results

*\*Organ Procurement and Transplantation Network (OPTN)*

# ABO Blood Type System

DONOR

RECIPIENT



Identical Matches  
Compatible Matches

# Methods

- Retrospective cohort analysis
- Data source: The United Network for Organ Sharing (UNOS), Organ Procurement and Transplantation Network (OPTN)
- All adult (>18) single-organ heart transplants were included
  - 10 year period: January 2000 – December 2009
- Primary stratification based on donor-recipient ABO matching
  - ABO blood type identical vs. compatible
- Outcome measures
  - Primary: all cause graft failure
  - Secondary: 30-day mortality, length of hospital stay, graft rejection, recipient cause of death

# Methods (cont.)

Univariate Analysis: Recipients



Univariate Analysis: Donors




Univariate Analysis:  
Kaplan-Meier Survival Curves



Multivariate Analysis:  
Cox Proportional Hazards

# Results

- January 2000 – December 2009:
  - 15,267 ABO identical transplants
  - 2,684 ABO compatible transplants






# Results – Univariate Analysis

Baseline demographic characteristics that were significantly different between the two cohorts ( $p < 0.05$ ):

- Donor & recipient ethnicity
- Donor history of cancer
- Recipient gender
- Recipient age
- Recipient waitlist status at transplant
- Recipient location before transplant
- Recipient life support
- Recipient total bilirubin
- Graft ischemic time

# Results – Kaplan Meier

ABO compatible transplants do not result in decreased survival compared to ABO identical transplants




# Results – Multivariate Analysis

Multivariate Cox Proportional Hazards Regression Model

Variable	Hazard Ratio (95% Confidence Limits)	p-Value*
<b>ABO compatible<sup>a</sup></b>	<b>0.99 (0.89-1.10)</b>	<b>0.87</b>
Gender (male vs. female)	0.95 (0.88-1.03)	0.24
Donor ethnicity <sup>b</sup>		
Black	1.08 (0.98-1.20)	0.14
Hispanic	1.00 (0.90-1.10)	0.95
Asian	1.13 (0.87-1.47)	0.37
Recipient ethnicity <sup>b</sup>		
<b>African American</b>	<b>1.42 (1.30-1.56)</b>	<b>&lt; 0.001</b>
Hispanic	1.09 (0.94-1.25)	0.25
Asian	0.92 (0.70-1.19)	0.52
Life support at transplant <sup>c</sup>		
All	1.07 (0.94-1.21)	0.32
IABP	0.98 (0.81-1.20)	0.85
<b>Ventilatory support</b>	<b>1.88 (1.50-2.37)</b>	<b>&lt; 0.001</b>
<b>ECMO</b>	<b>2.60 (1.72-3.83)</b>	<b>&lt; 0.001</b>
<b>Ischemic time</b>	<b>1.09 (1.06-1.13)</b>	<b>&lt; 0.001</b>
Waitlist status at transplant <sup>a</sup>		
Status 1B	1.00 (0.90-1.11)	0.95
Status 2	1.08 (0.94-1.23)	0.29
Status before transplant <sup>c</sup>		
<b>In ICU</b>	<b>1.24 (1.10-1.39)</b>	<b>&lt; 0.001</b>
In hospital (not ICU)	1.13 (0.99-1.28)	0.07
<b>Total bilirubin</b>	<b>1.03 (1.02-1.04)</b>	<b>&lt; 0.001</b>


# Results – Kaplan Meier

Grafts from blood type O donors are associated with poorer outcomes



# Results – Kaplan Meier

In ABO blood type B recipients, grafts from type O donors are associated with worse outcomes compared with type B donors



# Limitations

- Strength of the primary database
  - Completeness
  - Quality of predictor variables
- Accuracy of patient information
- We are confident, however, that any errors in patient data will not bias our results

# Conclusions

- ABO compatible heart transplantation does not result in adverse outcomes with respect to graft survival and incidence of acute rejection compared with ABO identical grafts
  - Therefore, ABO compatible and identical hearts should be viewed equally in clinical decision making
- Possible exception: ABO blood type O donors are associated with poorer outcomes, especially when given to type B recipients
- The impact of above findings on donor allocation for type B recipients may need to be investigated further

**THANK YOU**